Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434982 | 0.77 | HDAC8 (0.56) | ALDH1A1HDAC6HDAC1GAAHDAC2 | |
| SCHEMBL3524140 | 0.76 | NAPRT (0.55) | ALDH1A1HDAC6HDAC1CYP1A2CYP3A4 | |
| SCHEMBL838150 | 0.76 | CA2 (0.46) | ALDH1A1CYP2C19HDAC2HDAC8RAB9A | |
| SCHEMBL1965925 | 0.76 | IDO1 (0.45) | NPC1SMN1; SMN2 | |
| SCHEMBL23586287 | 0.74 | ALDH1A1 (0.42) | ALDH1A1HDAC6CYP3A4MAPTLOXL2 | |
| SCHEMBL641405 | 0.74 | IDO1 (0.44) | ALDH1A1HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL641565 | 0.74 | GAA (0.46) | ALDH1A1GAALOXL2RAB9ASMN1; SMN2 | |
| SCHEMBL480288 | 0.74 | CYP3A4 (0.35) | HDAC6CYP1A2CYP3A4CYP2D6HDAC8 | |
| SCHEMBL1580990 | 0.74 | IDO1 (0.44) | ALDH1A1HDAC6HDAC1GAARAB9A | |
| Hydroxyamine SCHEMBL7974827 | 0.74 | KMT2A (0.52) | ALDH1A1HDAC6CYP3A4GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1711491-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | Prosidion Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005061489-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| EP-1140920-A1 | PIPERIDINES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2000039125-A1 | PIPERIDINES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | GPR119, GCGR, GLP1R | ALDH1A1 1770/4885HDAC6 2872/4885HDAC1 1471/4885 |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | ALDH1A1 1866/4885HDAC6 1777/4885HDAC1 454/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | ALDH1A1 549/4885HDAC6 1249/4885HDAC1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.